Genenta Science S.p.A.

Develops cell & gene therapies using engineered stem cells to treat solid tumors.

GNTA | NDAQ

Overview

Corporate Details

ISIN(s):: US36870W1009
LEI:
Country:: United States of America
Address:: OLGETTINA, NO. 58, 20132 MILAN
Website:: https://www.genenta.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Genenta Science S.p.A. is a clinical-stage immuno-oncology company developing proprietary cell and gene therapies for the treatment of solid tumors. The company's technology is centered on engineering a patient's own hematopoietic stem cells using a lentiviral vector to combat cancer. Its lead candidate, Temferon, is designed to make tumors visible to the immune system by reprogramming the tumor microenvironment and breaking immune tolerance. Genenta has completed a Phase 1 clinical trial in Glioblastoma Multiforme and has initiated a Phase 1/2a study in metastatic Renal Cell Carcinoma. The treatments are designed as one-time monotherapies that also have the potential to be used in combination to enhance the efficacy of other therapeutics, such as immune checkpoint inhibitors.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Genenta Science S.p.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Genenta Science S.p.A.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Genenta Science S.p.A. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Clearmind Medicine Inc. Develops psychedelic-derived medicines for Alcohol Use Disorder and mental health conditions.	United States of America	CMND
Clearside Biomedical, Inc. Developing therapies for back-of-the-eye diseases via proprietary suprachoroidal delivery.	United States of America	CLSD
Clene Inc. Developing nanocrystal therapies for neurodegenerative diseases like ALS and MS.	United States of America	CLNN
Climb Bio, Inc. Clinical-stage biotech developing monoclonal antibodies for immune-mediated diseases.	United States of America	CLYM
CMG Pharmaceutical Co., Ltd. Develops and manufactures prescription drugs, specializing in Oral Thin Film (OTF) technology.	South Korea	058820
Cocrystal Pharma, Inc. Develops novel antiviral drugs for influenza, coronaviruses, norovirus, and hepatitis C.	United States of America	COCP
Co-Diagnostics, Inc. Develops patented PCR solutions for accurate infectious disease diagnostics.	United States of America	CODX
co.don AG Develops personalized cartilage cell transplants for minimally invasive joint repair.	Germany	CNW
Coeptis Therapeutics Holdings, Inc. Develops cell therapy platforms for cancer, autoimmune, and infectious diseases.	United States of America	COEP
COGNITION THERAPEUTICS INC Clinical-stage biopharma developing small-molecule drugs for Alzheimer's and dementia.	United States of America	CGTX